Mesenchymal Stem Cell Therapy-Is the Vessel Half Full or Half Empty?

Area of Science:

• Biomedical science
• Regenerative medicine
• Immunology

Background:

• Severe COVID-19 pneumonia lacks effective pathogen-destroying therapies.
• Mesenchymal stem cells (MSCs) are investigated for treating inflammatory diseases.
• Existing data on MSCs for COVID-19 are limited regarding mechanisms and safety.

Purpose of the Study:

• To evaluate the potential of mesenchymal stem cells (MSCs) in treating severe COVID-19 pneumonia.
• To address the need for effective therapeutic strategies against SARS-CoV-2.
• To highlight the necessity for further research into MSC-based therapies.

Main Methods:

• Review of scientific literature on MSCs and their application in inflammatory conditions.
• Analysis of existing data on MSCs' mechanisms of action and safety profiles.
• Discussion of the requirements for clinical studies and regulatory approval.

Main Results:

• MSCs possess scientifically justified anti-inflammatory properties relevant to pneumonia.
• Significant gaps exist in understanding MSCs' systemic administration effects, biodistribution, and long-term consequences in humans.
• Pre-clinical data on MSC efficacy and safety in COVID-19 models are contradictory.

Conclusions:

• Further experimental verification of MSCs' specific action and risks in COVID-19 is crucial.
• Clinical studies demonstrating an acceptable risk/benefit ratio are required for MSCs' medical practice introduction.
• A framework for accelerated yet justified approval of cell-based products is needed.